$A (Agilent Technologies Inc.)

$A {{ '2016-05-16T20:24:09+0000' | timeago}} • Announcement

Laboratory instruments and services provider $A reported higher 2Q16 net income as a result of higher revenues. Net income was $91MM or $0.28 per diluted share compared to $87MM or $0.26 per diluted share in 2Q15. Revenue of $1.02Bil was up 6% YoverY for 2Q16. Non-GAAP income from continuing operations was $145MM or $0.44 per share.

$A {{ '2017-07-19T12:28:12+0000' | timeago}} • Announcement

$A has appointed Hans E Bishop to its BoD. Bishop is a co-founder and CEO of Seattle-based biopharmaceutical firm Juno Therapeutics. He has held various executive positions in the pharmaceutical industry, including as COO of Dendreon.

$A {{ '2017-07-17T17:47:21+0000' | timeago}} • Announcement

$A introduced a new sequencing library prep solution, Agilent SureSelectXTHS. SureSelectXTHS is a streamlined, high-sensitivity solution for research, optimized for labs with a requirement to sequence DNA from formalin-fixed paraffin-embedded (FFPE) samples, which may have degraded over time.

$A {{ '2017-07-07T15:46:38+0000' | timeago}} • Announcement

Analytical laboratory technology provider $A has acquired UK-based Cobalt Light Systems, a provider of Raman spectroscopic instruments, for GBP 40MM in cash. After completion of the deal, Cobalt’s CEO will remain with Agilent as Director of Raman Spectroscopy. Agilent’s global center for Raman spectroscopy will be Oxford.

$A {{ '2017-06-06T18:09:45+0000' | timeago}} • Announcement

$A has launched a high-resolution, accurate-mass system designed for laboratories engaged in food and environmental testing, life science research, forensics and chemical analysis. The system allows scientists to employ analytical techniques that were not previously practical and facilitate greater exploration of unknown chemical samples.

$A {{ '2017-06-02T16:05:23+0000' | timeago}} • Announcement

$A and Agendia Inc. agreed to expand their relationship to include the development of an RNA-Seq kit version of Agendia's currently marketed MammaPrint and BluePrint tests. The agreement accelerates the development of tests to help assess risk of disease recurrence in women with early-stage breast cancer.

$A {{ '2017-05-22T21:29:30+0000' | timeago}} • Webcast

$A saw overall growth in China in the high single digits for 2Q17. The end market demand remains healthy and the company expects growth in the low double digits in 2017. $A remains positive in its expectations for China going forward.

$A {{ '2017-05-22T21:12:32+0000' | timeago}} • Webcast

$A said in terms of its chemical and energy market segmentation, about 15% of its business is in exploration which remains down. About 35% is in the refining area where the company is seeing some levels of reinvestment. The other 50% is in chemical where some investments are starting up. All in all, about 85% of the segment shows growth potential.

$A {{ '2017-05-22T21:04:31+0000' | timeago}} • Webcast

$A had strong performance in the chemical and energy as well as environmental markets in 2Q17 and one of the contributors was the performance of the gas chromatography business which had high single digit growth.

$A {{ '2017-05-22T20:48:25+0000' | timeago}} • Infographic

$A Agilent Technologies, Inc. Earnings AlphaGraphics: Q2 2017 highlights

$A {{ '2017-05-22T20:48:20+0000' | timeago}} • Webcast

During 2Q17, $A saw growth well above expectations in the chemical and energy, pharma and European markets while the Asia business remained strong. The company saw a stronger-than-expected pickup in the chemical and energy market with 14% core growth. Core growth in pharma at 12% exceeded expectations.

$A {{ '2017-05-22T20:24:54+0000' | timeago}} • Announcement

$A sees 3Q17 revenue in the range of $1.06Bil to $1.08Bil, with non-GAAP earnings of $0.49-0.51 per share. For FY17, Agilent expects revenue of $4.36-4.38Bil and non-GAAP earnings of $2.15-2.21 per share.

$A {{ '2017-05-22T20:22:46+0000' | timeago}} • Announcement

In 2Q17, $A's Life Sciences and Applied Markets Group (LSAG) revenue grew 6% to $523MM, while revenue from CrossLab Group (ACG) improved 9% to $378MM. Second-quarter revenue from Agilent’s Diagnostics and Genomics Group (DGG) rose 13% to $201MM.

$A {{ '2017-05-22T20:20:17+0000' | timeago}} • Announcement

The net revenue of $A improved 8% to $1.10Bil in 2Q17, with the analytical laboratory instrument maker posting an 80% spike in net income of $164MM from last year's 91MM. Earnings jumped to $0.50 per diluted share from $0.28 a share, as SG&A expenses fell 3% to $307MM and income from ops rose 53% to $201MM.

$A {{ '2017-05-18T12:44:18+0000' | timeago}} • Announcement

The BoD of $A declared a quarterly dividend of 13.2 cents per share of common stock. The dividend will be paid on July 26, 2017, to all shareholders of record as of the close of business on July 3, 2017.

$A {{ '2017-05-17T21:22:18+0000' | timeago}} • Announcement

The BoD of $A declared a quarterly dividend of 13.2 cents per share of common stock. The dividend will be paid on July 26, 2017, to all shareholders of record as of the close of business on July 3, 2017.

$A {{ '2017-05-15T11:43:30+0000' | timeago}} • Announcement

$A announced the expanded use of its Dako PD-L1 IHC 28-8 pharmDx test for squamous cell carcinoma of the head and neck (SCCHN), the most prevalent type of head and neck cancer. Europe is the first region to launch a PD-L1 CE-IVD test for SCCHN globally.

$A {{ '2017-03-21T17:43:52+0000' | timeago}} • Announcement

$A introduced a new target enrichment solution for next-generation DNA sequencing. Agilent SureSelect Clinical Research Exome V2 delivers more than 1,000 additional, disease relevant targets compared to the company's earlier version of the product.

$A {{ '2017-03-15T20:38:38+0000' | timeago}} • Announcement

Life sciences company $A announces a cash dividend of 13.2 cents per share. The dividend will be paid on April 26, 2017, to all shareholders of record as of April 4, 2017.

$A {{ '2017-03-15T20:34:42+0000' | timeago}} • Announcement

Laboratory equipment maker $A elects Koh Boon Hwee as the Chairman of the Board. He will succeed James Cullen, who will continue as a director. Boon Hwee currently serves as the non-executive chairman of Sunningdale Tech Ltd.

$A {{ '2017-02-14T22:23:30+0000' | timeago}} • Webcast

$A said that on PD-L1, the company is very pleased with its uptick last year. The company expects a pickup again in 2017. $A added that it does see a contribution from PD-L1 to its performance but doesn't think it will bring the company up to the double digit growth area.

Recent Transcripts

PKE (Park Electrochemical Corp.)
Wednesday, June 28 2017 - 3:00pm
MEI (Methode Electronics, Inc.)
Thursday, June 22 2017 - 3:00pm
GIGA (Giga-tronics Inc.)
Tuesday, June 20 2017 - 8:30pm
JBL (Jabil Circuit Inc.)
Wednesday, June 14 2017 - 8:30pm
MRVL (Marvell Technology Group Ltd.)
Thursday, May 25 2017 - 8:45pm
A (Agilent Technologies Inc.)
Monday, May 22 2017 - 8:30pm
CSCO (Cisco Systems, Inc.)
Wednesday, May 17 2017 - 8:30pm
UQM (UQM Technologies Inc.)
Thursday, May 11 2017 - 8:30pm
SPA (Sparton Corp.)
Wednesday, May 10 2017 - 3:00pm
KEM (KEMET Corp.)
Wednesday, May 10 2017 - 1:00pm
MCHP (Microchip Technology Inc.)
Tuesday, May 9 2017 - 9:00pm
NVDA (NVIDIA Corporation)
Tuesday, May 9 2017 - 9:00pm
VPG (Vishay Precision Group, Inc.)
Tuesday, May 9 2017 - 2:00pm
CVU (CPI Aerostructures Inc.)
Tuesday, May 9 2017 - 12:30pm
COMM (CommScope Holding Company, Inc.)
Thursday, May 4 2017 - 12:30pm
VSH (Vishay Intertechnology Inc.)
Wednesday, May 3 2017 - 1:00pm
QGEN (Qiagen NV)
Wednesday, May 3 2017 - 1:00pm
LBY (Libbey Inc.)
Tuesday, May 2 2017 - 3:00pm
PKE (Park Electrochemical Corp.)
Tuesday, May 2 2017 - 3:00pm
XYL (Xylem Inc.)
Tuesday, May 2 2017 - 1:00pm

AlphaGraphics you may like